Liquid Biopsy for Early Cancer Detection (Galleri / Grail) — Diagnostics & Biomarker Testing
Blood-based multi-cancer early detection test analyzing circulating tumor DNA methylation patterns to detect 50+ cancer types — often before symptoms or standard screening.
Overview
Liquid biopsy cancer screening analyzes cell-free DNA (cfDNA) fragments shed into the bloodstream by cancer cells. The Galleri test (Grail, acquired by Illumina) uses methylation sequencing of cfDNA to detect cancer signals and predict the organ of origin for 50+ cancer types with a single blood draw. The PATHFINDER study (n=6,662 adults, JAMA 2023) demonstrated Galleri sensitivity of ~29% across all stages (higher for late-stage, lower for early-stage) with a positive predictive value of 38% (1% false positive rate). Sensitivity increases with cancer stage: ~17% for stage I, ~77% for stage III-IV. The SYMPLIFY trial (UK, NEJM 2023) confirmed utility in symptomatic patients. NHS England enrolled 140,000 participants in the SUMMIT trial. Crucially, Galleri detects cancers (pancreatic, ovarian, esophageal) for which no standard screening exists. The test does not replace existing screenings (mammogram, colonoscopy, PSA) but complements them.
Indications
- Multi-cancer early detection (50+ cancer types from single blood draw)
- Cancers without existing screening tests (pancreatic, ovarian, esophageal)
- High-risk individuals (BRCA+, Lynch syndrome, strong family history)
- Annual longevity cancer surveillance program
- Complementing standard cancer screens
Mechanism of Action
Cancer cells shed DNA fragments into the bloodstream as they die (apoptosis/necrosis); ctDNA carries cancer-specific methylation patterns distinct from normal cell-free DNA
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Galleri Test (Grail) | Single blood draw (50 mL) | Annually | ~$949/test; prescription required; not covered by most insurance; Medicare coverage under evaluation |
Evidence Grade
GRADE C
Safety & Contraindications
- 1% false positive rate: 1 in 100 cancer-free patients will receive a false positive, triggering anxiety and diagnostic workup
- Low sensitivity for stage I cancer (~17%): a negative result does not rule out early cancer
- Positive result requires imaging and tissue biopsy for confirmation — cannot diagnose cancer alone
- Psychological burden of uncertain positive results can be substantial
- Not FDA-approved yet (Breakthrough Device Designation granted); available as a lab-developed test (LDT)